Stakeholder Perspectives: Influenza Vaccines - Flying back Into Flu

Introduction

Influenza is a highly infectious disease which globally infects 10-20% of the population every year causing up to 500,000 deaths. Although all persons are at risk, the elderly and the young are the most vulnerable. For decades, trivalent prophylactic vaccines produced in chicken eggs have been used to reduce the burden of influenza with approximately 300 million doses produced globally.

Scope

Evaluation of total 2004 global vaccine market value, historical growth since 1999 and major company market share

Overview of major influenza vaccine products, producers and new product development

Expert led discussion of drivers and resistors to cell culture flu systems in seasonal/pandemic scenarios

Forecast value and demand (doses) for influenza vaccines in 2010 with launch predictions

Highlights

Despite the Chiron debacle, collective sales of influenza vaccines from Western producers surpassed the $1 billion level in 2004 with 10% growth over the previous year. Expanding recommendations for vaccination continue to fuel global demand.

Datamonitor forecasts that in the seven major markets demand for influenza vaccines will expand to 370 million doses and a market value of $3.7 billion by 2010. Global capacity will expand appropriately to meet this goal but competition will intensify with 11 predicted new product launches.

Cell culture flu could amount to 15% of US doses supplied in 2010 if the FDA can overcome safety concerns with the MDCK line. Although heralded as a much needed solution, cell culture flu still requires substantial capital investment.

Reasons to Purchase

Review an up to date expert discussion of major dynamics within the global vaccine market

Gain insight into how the market for influenza vaccines is now an attractive growth option

Understand commercial drivers and resistors for cell culture flu systems

December 2005

Pages: 166

Format: PDF
Table of Contents
Price: $7,600.00 / GBP3,800.00